HC Wainwright Forecasts Cytosorbents FY2028 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Cytosorbents in a research note issued to investors on Thursday, April 3rd. HC Wainwright analyst S. Lee anticipates that the medical research company will earn ($0.07) per share for the year. HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.05) EPS.

Other analysts have also issued reports about the stock. StockNews.com started coverage on shares of Cytosorbents in a research report on Thursday. They set a “hold” rating for the company. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Price Performance

Shares of Cytosorbents stock opened at $0.97 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61. The company has a fifty day moving average of $1.07 and a 200-day moving average of $1.04. The stock has a market capitalization of $53.04 million, a price-to-earnings ratio of -2.69 and a beta of 0.78.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04. The business had revenue of $9.20 million during the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in shares of Cytosorbents in the fourth quarter valued at about $30,000. Northern Trust Corp grew its stake in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Avenir Corp increased its holdings in Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after purchasing an additional 118,387 shares during the period. Raymond James Financial Inc. purchased a new position in Cytosorbents during the 4th quarter valued at about $99,000. Finally, Renaissance Technologies LLC raised its position in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 8,400 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.